You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEthchlorvynol
Accession NumberDB00189  (APRD00958)
TypeSmall Molecule
GroupsApproved, Illicit, Withdrawn
DescriptionEthchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. [Wikipedia]
Structure
Thumb
Synonyms
1-chloro-3-ethyl-1-penten-4-yn-3-ol
1-Chloro-3-ethyl-pent-1-en-4-yn-3-ol
3-(beta-chlorovinyl)-1-pentyn-3-ol
3-(β-chlorovinyl)-1-pentyn-3-ol
ethyl β-chlorovinyl ethynyl carbinol
Placidyl
β-chlorovinyl ethyl ethynyl carbinol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Placidyl Cap 200mgCapsule200 mgOralAbbott Laboratories, Limited1956-12-312008-06-10Canada
Placidyl Cap 500mgCapsule500 mgOralAbbott Laboratories, Limited1952-12-312008-06-06Canada
Placidyl Cap 750mgCapsule750 mgOralAbbott Laboratories, Limited1971-12-312008-06-06Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArvynolPfizer
NostelDainippon
PlacidylAbbott
RoeridormPfizer-Roerig
SerenesilAbbott
Brand mixturesNot Available
SaltsNot Available
Categories
UNII6EIM3851UZ
CAS number113-18-8
WeightAverage: 144.599
Monoisotopic: 144.034192617
Chemical FormulaC7H9ClO
InChI KeyZEHYJZXQEQOSON-AATRIKPKSA-N
InChI
InChI=1S/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+
IUPAC Name
1-chloro-3-ethylpent-1-en-4-yn-3-ol
SMILES
[H]C(Cl)=CC(O)(CC)C#C
Pharmacology
IndicationUsed for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents.
Structured Indications Not Available
PharmacodynamicsEthchlorvynol is a sedative drug and schedule IV (USA) controlled substance. It produces cerebral depression, however the exact mechanism of action is not known.
Mechanism of actionAlthough the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
TargetKindPharmacological actionActionsOrganismUniProt ID
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Related Articles
AbsorptionRapidly absorbed from gastrointestinal tract.
Volume of distributionNot Available
Protein binding35-50%
Metabolism

About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation.

Route of eliminationNot Available
Half lifePlasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include thrombocytopenia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alprazolam.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Azaperone.Vet Approved
AzelastineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bupivacaine.Approved, Investigational
BuprenorphineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butabarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butorphanol.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clorazepate.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Codeine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclobenzaprine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diazepam.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eszopiclone.Approved
EthanolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethchlorvynol.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hexobarbital.Approved
HydrocodoneEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Indalpine.Investigational, Withdrawn
IsofluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Isoflurane.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethchlorvynol.Approved
LoxapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methohexital.Approved
MethotrimeprazineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methylphenobarbital.Approved
MetyrosineEthchlorvynol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Investigational
MirtazapineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Morphine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nalbuphine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Opium.Approved, Illicit
OrphenadrineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paliperidone.Approved
ParaldehydeEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved
PerazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pethidine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pomalidomide.Approved
PramipexoleEthchlorvynol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pregabalin.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quetiapine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Reserpine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Romifidine.Vet Approved
RopiniroleEthchlorvynol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ropivacaine.Approved
RotigotineEthchlorvynol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethchlorvynol.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Secobarbital.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sulpiride.Approved
SuvorexantEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Temazepam.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrodotoxin.Investigational
ThalidomideEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zolazepam.Vet Approved
ZolpidemEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol
  • Take with food to reduce irritation.
References
Synthesis Reference

Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas.
Pfizer & Co., Inc.

General ReferencesNot Available
External Links
ATC CodesN05CM08
AHFS Codes
  • 28:24.92
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier+0.9685
Caco-2 permeable+0.646
P-glycoprotein substrateNon-substrate0.743
P-glycoprotein inhibitor INon-inhibitor0.9023
P-glycoprotein inhibitor IINon-inhibitor0.9672
Renal organic cation transporterNon-inhibitor0.9589
CYP450 2C9 substrateNon-substrate0.7267
CYP450 2D6 substrateNon-substrate0.9
CYP450 3A4 substrateNon-substrate0.6176
CYP450 1A2 substrateNon-inhibitor0.5224
CYP450 2C9 inhibitorNon-inhibitor0.6241
CYP450 2D6 inhibitorNon-inhibitor0.9316
CYP450 2C19 inhibitorInhibitor0.5539
CYP450 3A4 inhibitorNon-inhibitor0.7814
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7382
Ames testAMES toxic0.867
CarcinogenicityCarcinogens 0.8102
BiodegradationNot ready biodegradable0.9614
Rat acute toxicity2.7881 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9406
hERG inhibition (predictor II)Non-inhibitor0.9289
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Banner pharmacaps inc
  • Abbott laboratories pharmaceutical products div
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral200 mg
CapsuleOral500 mg
CapsuleOral750 mg
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
boiling point28.5-30Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas. Pfizer & Co., Inc.
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.143 mg/mLALOGPS
logP1.45ALOGPS
logP1.62ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)12.88ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area20.23 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity38.64 m3·mol-1ChemAxon
Polarizability14.77 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as ynones. These are organic compounds containing the ynone functional group, an alpha,beta unsaturated ketone group with the general structure RC#C-C(=O)R' (R' not H).
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbonyl compounds
Sub ClassAlpha,beta-unsaturated carbonyl compounds
Direct ParentYnones
Alternative Parents
Substituents
  • Ynone
  • Tertiary alcohol
  • Chloroalkene
  • Haloalkene
  • Vinyl halide
  • Vinyl chloride
  • Hydrocarbon derivative
  • Organochloride
  • Organohalogen compound
  • Alcohol
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Smeyatsky N, Baldwin D, Botros W, Gura R, Kurian T, Lambert MT, Patel AG, Steinert J, Priest RG: The treatment of sleep disorders. S Afr Med J. 1992 May 2;Suppl:1-8. [PubMed:1585214 ]
  2. ChEMBL Compound Report Card [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23